Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with MYC/BCL2 double-hit (DH) represents a distinct entity with dismal prognosis after standard immunochemotherapy in the current WHO lymphoma classification. However, whether TP...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Res
Hauptverfasser: Deng, Manman, Xu-Monette, Zijun Y., Pham, Lan V., Wang, Xudong, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Visco, Carlo, Bhagat, Govind, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Parsons, Benjamin M., Hagemeister, Fredrick, van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, Liu, Phillip, Young, Ken H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092941/
https://ncbi.nlm.nih.gov/pubmed/33154093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-20-0466
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge